
🎤 Country singer @TheJulieRoberts shares how living with #MS, personal setbacks, and music shaped her journey of resilience. 🎧 New #MSLivingWell podcast bit.ly/4BSaveT🍎apple.co/4zI9Jjk @MSViewsandNews @Brandon_Beaber @DocforMS @DrAnnetteOkai

Director, MS Center for Innovations in Care. 🧠 doctor helping people live well with multiple sclerosis. Podcast host: apple.co/3mwg1Mo Tweets ≠ medical advice

🎤 Country singer @TheJulieRoberts shares how living with #MS, personal setbacks, and music shaped her journey of resilience. 🎧 New #MSLivingWell podcast bit.ly/4BSaveT🍎apple.co/4zI9Jjk @MSViewsandNews @Brandon_Beaber @DocforMS @DrAnnetteOkai

🎧 Author @MattCavallo shares how a devastating MS attack at age 28 changed his life—and how he found a way forward. New #MSLivingWell podcast on resilience. bit.ly/4BSaveT🍎apple.co/4zI9Jjk @MarkWebb_ @DanJenDig @KlausSchmierer Sponsor: @TGTherapeutics


Wiendl: Phase 3 REMODEL trials: #Remibrutinib reduced relapses by 31–35%, new T2 lesions by 65–70%, 3-month CDP by 20.5% (p=0.09) & 6-month CDP by 29.2% (p=0.038) vs teriflunomide. No major liver safety signal. #MSTORONTO2026

Oh: Phase 3 fenebrutinib reduced slowly expanding lesion (SEL) counts by 21.5% vs ocrelizumab in PPMS and 18.3% vs teriflunomide in RMS. SEL volumes reduced 27.5% and 30.5%, respectively. Fewer patients on fenebrutinib accumulated PRLs. #MSTORONTO2026


Ontaneda: First Phase 1 results of off-the-shelf CD19 CAR T-cell therapy (azer-cel) in progressive MS (n=26). No dose-limiting toxicities; EDSS stable/improved in 16/18 at Day 90. Early data; follow-up ongoing. #MSTORONTO2026

Eshaghi: AI can be used in reading MRI scans for #MS including cerebral lesions, brain volumetrics, cord atrophy and cord lesions. Future development may redefine prognostic capability. #MSTORONTO2026

Alping: Risk of inflammatory bowel disease on rituximab increased. 62% of IBD events were classified as Crohn's disease. Number Needed to Harm: 131 patients over 5 years. #MSTORONTO2026

Varjú: Danish #MS registry shows a dramatic shift in switch from escalation strategy to early use of high efficacy treatment. No difference in PIRA outcomes between these approaches. 🤔 Controlling for all variables seems challenging…. #MSTORONTO2026

Checkout my @ECTRIMS poster. ENHANCE study: #MS patients switching from ocrelizumab to #ublituximab had 69% reduction in wearing-off at week 24. Patients with B cells despite ocrelizumab became depleted on ublituximab. 👉bit.ly/4iycUUh #MSTORONTO2026

Sormani: Pooled FENhance 1 and 2 RMS. Fenebrutinib compared to teriflunomide ⬇️relapses 55%, ⬇️ enhancing lesions 75% and ⬇️ new/enlarging T2 80%. Composite disability results below. #MSTORONTO2026

Excited to arrive at @ECTRIMS in Toronto to share and learn about the latest developments in multiple sclerosis. Looking forward to real progress for people living with #MS globally. 🌎Updates to follow! #MSTORONTO2026

Sleep fixes sleepiness. It doesn't always fix MS fatigue. New MS Living Well Pod 🎧: @RonaMossMorris @KingsCollegeLon shares what really works. bit.ly/4yXOeKG 🍎apple.co/4yB40KP #MSToronto2026 @KlausSchmierer @C_OrejaGuevara @DocforMS Sponsor: @TGTherapeutics

Sleep fixes sleepiness. It doesn't always fix MS fatigue. New #MSLivingWell Pod 🎧 @brainboyneuro1 talks @RonaMossMorris about what actually helps you get your energy back! bit.ly/4yXOeKG 🍎apple.co/4yB40KP @Brandon_Beaber @themsguide @MSViewsandNews @MarkWebb_

Worried your MS therapy raises your cancer risk? The long-term data may surprise you. New #MSLivingWell episode🎧Drs. Esther Melamed & Melinda Magyari; Host @brainboyneuro1 bit.ly/3TdjnKM 🍏apple.co/46HoeXF @MStranslate @MustStopMS @themsguide @MarkWebb_